Leonhardt Harry J

GC & Chief Compliance OfficerPoseida Therapeutics, Inc. (PSTX) · full profile →Form 4 · filed Jan 8, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
1 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 8, 2025Tender(U)224K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 8, 2025Disposed to issuer(D)160K$00
Jan 8, 2025Disposed to issuer(D)137K$00
Jan 8, 2025Disposed to issuer(D)73K$00
Jan 8, 2025Disposed to issuer(D)125K$00
Jan 8, 2025Disposed to issuer(D)112K$00

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-001082) within minutes of acceptance. Every field above traces to the original document. Verify it directly: